Affinage

WDR26

WD repeat-containing protein 26 · UniProt Q9H7D7

Length
661 aa
Mass
72.1 kDa
Annotated
2026-06-11
22 papers in source corpus 15 papers cited in narrative 15 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

WDR26 is a WD40-repeat, Gβ-like protein that operates in two convergent regulatory modes: as a substrate-receptor and architectural subunit of the CTLH/GID E3 ubiquitin ligase complex, and as a signaling scaffold downstream of G-protein-coupled receptors (PMID:22065575, PMID:38759627). Through its LisH-CTLH and WD40 domains, WDR26 homodimerizes to bridge two core-CTLH complexes into supramolecular oval-shaped assemblies, and it functions as a non-canonical substrate receptor that recognizes degron motifs on target proteins to direct their ubiquitylation and proteasomal degradation (PMID:38759627, PMID:38575527). Identified substrates span diverse processes — NMNAT1 (with the recognition controlled by YPEL5 degron mimicry), the pyrimidine-salvage enzyme UCK2 during mTORC1 inhibition, the transcriptional repressor HBP1, lamin B during terminal erythropoiesis, and the transcriptional coactivator RUNX1T1 (PMID:38759627, PMID:39808525, PMID:38575527, PMID:31945154, PMID:42138082). WDR26 and muskelin β-propeller proteins compete interchangeably for the CTLH scaffold, forming distinct complexes with separate proteomes and thereby dictating substrate selectivity and overall CTLH ligase output (PMID:39702571). In its scaffolding role, WDR26 directly binds free Gβγ and PLCβ2 and assembles a Gβγ–PI3Kβ–AKT2 complex that selectively amplifies GPCR-stimulated PLCβ and PI3K/AKT signaling, supporting leukocyte chemotaxis and, in breast cancer, tumor growth and metastasis (PMID:22065575, PMID:23625927, PMID:26895380). WDR26 loss-of-function causes the neurodevelopmental disorder Skraban-Deardorff syndrome: haploinsufficiency stabilizes RUNX1T1, elevating MAP2 and disrupting dendritic and synaptic architecture, and patient variants impair CTLH assembly or destabilize WDR26 itself through accelerated proteasomal degradation or nonsense-mediated decay (PMID:42138082, PMID:38575527, PMID:40826479).

Mechanistic history

Synthesis pass · year-by-year structured walk · 11 steps
  1. 2004 Medium

    Established WDR26 as a Gβ-like WD40 protein with a regulatory role in signaling, first framed as a negative regulator of the MEKK1-driven MAPK pathway.

    Evidence Overexpression with ELK-1/SRE luciferase reporter assays downstream of MEKK1

    PMID:15378603

    Open questions at the time
    • Effect shown only by overexpression reporter assays
    • No direct binding partner or biochemical mechanism for MAPK suppression identified
  2. 2011 High

    Defined WDR26's first concrete molecular function — direct Gβγ binding required for downstream PLCβ/PI3K activation and leukocyte chemotaxis — moving it from a phenotypic regulator to a defined signaling effector.

    Evidence In vitro direct binding, reciprocal Co-IP of endogenous Gβγ, siRNA knockdown with chemotaxis/in vivo homing readouts in Jurkat T cells and SCID mice

    PMID:22065575

    Open questions at the time
    • Structural basis of Gβγ binding not resolved
    • Relationship to its later-described CTLH role not addressed
  3. 2013 High

    Refined the scaffolding mechanism, showing WDR26 simultaneously binds Gβγ and PLCβ2 and oligomerizes via LisH-CTLH and WD40 domains to promote PLCβ2 membrane translocation and activation.

    Evidence Direct binding, Co-IP, deletion-mutant domain mapping, fluorescence imaging of PLCβ2 translocation, PLCβ2 activity assays

    PMID:23625927

    Open questions at the time
    • Did not connect oligomerization domains to E3 ligase scaffolding function later attributed to the same domains
    • Stoichiometry of the higher-order assembly not defined
  4. 2016 High

    Showed the WDR26 scaffold has receptor-selective output, assembling a Gβγ–PI3Kβ–AKT2 complex that drives GPCR- but not EGFR-stimulated PI3K/AKT signaling and promotes tumor growth and metastasis.

    Evidence siRNA knockdown, complex-disrupting WDR26 mutants, pAKT/pPI3K assays, orthotopic xenograft mouse model

    PMID:26895380

    Open questions at the time
    • Did not address whether CTLH-associated WDR26 contributes to or is separate from this signaling pool
  5. 2016 Medium

    Linked WDR26 to ubiquitin-dependent degradation in additional pathways — Axin1-dependent β-catenin turnover and Parkin-mediated mitophagy — early hints of a broader proteostatic role.

    Evidence Co-IP, β-catenin ubiquitination and Wnt reporter assays; Parkin translocation imaging and mitochondrial ubiquitination assays in H9c2 cells

    PMID:27098453 PMID:27797717

    Open questions at the time
    • No in vitro reconstitution of the ubiquitination events
    • Mechanistic relationship to CTLH complex not established at the time
  6. 2020 High

    Placed WDR26 firmly within the GID/CTLH E3 ligase and identified its first physiological substrate, lamin B, establishing a complex→substrate→phenotype axis in erythropoiesis.

    Evidence Mouse Wdr26 knockout erythroblasts and zebrafish knockdown, lamin B ubiquitination/level assays, CTLH/GID Co-IP

    PMID:31945154

    Open questions at the time
    • Did not define how WDR26 recognizes lamin B as a degron-bearing substrate
    • Generality of receptor function across substrates untested
  7. 2024 High

    Resolved the structural and mechanistic basis of WDR26 substrate receptor activity, showing it reads an internal basic degron on NMNAT1 and is competitively inhibited by YPEL5 N-terminal degron mimicry.

    Evidence Cryo-EM of NMNAT1- and YPEL5-bound WDR26-CTLH complexes, in vitro ubiquitylation, degron mutagenesis, cellular degradation and YPEL5 perturbation assays

    PMID:38759627

    Open questions at the time
    • Whether all WDR26 substrates use a common degron architecture unknown
    • Physiological triggers gating NMNAT1 degradation not defined
  8. 2024 High

    Defined WDR26's architectural role and its substrate-selection logic: homodimers bridge two core-CTLH complexes into supramolecular assemblies, and WDR26 competes interchangeably with muskelin to set distinct CTLH proteomes.

    Evidence Structural modeling and complementation in WDR26-KO cells; reciprocal WDR26/muskelin KO cell lines with quantitative proteomics, Co-IP, and ubiquitin assays

    PMID:38575527 PMID:39702571

    Open questions at the time
    • Signals controlling the WDR26-versus-muskelin choice not identified
    • Function of the supramolecular oval assembly beyond scaffold bridging unclear
  9. 2025 High

    Connected WDR26-CTLH activity to nutrient/growth signaling by showing it degrades the pyrimidine-salvage enzyme UCK2 during mTORC1 inhibition, with UCK1 modulating UCK2 localization.

    Evidence Rapamycin-induced mTORC1 inhibition with WDR26/CTLH knockdown, UCK2 half-life, ubiquitination, and localization assays

    PMID:39808525

    Open questions at the time
    • How mTORC1 status is transduced to WDR26-CTLH activity unresolved
    • Degron on UCK2 not mapped
  10. 2024 High

    Established the disease mechanism of Skraban-Deardorff syndrome: in vivo, Wdr26 haploinsufficiency stabilizes RUNX1T1, elevating MAP2 and disrupting neuronal architecture, with knockdown of Runx1t1 rescuing the phenotype.

    Evidence Wdr26 heterozygous KO mice, RUNX1T1 ubiquitination assays, MAP2 measurement, AAV-shRNA Runx1t1 rescue, behavioral testing

    PMID:42138082

    Open questions at the time
    • Other CTLH substrates contributing to neurodevelopmental phenotype not fully cataloged
  11. 2025 Medium

    Explained how patient variants cause loss of function — missense variants accelerate WDR26 proteasomal degradation while a frameshift triggers NMD — unifying the genetic findings at the protein-stability level.

    Evidence Cycloheximide chase, proteasome inhibitor rescue, mRNA stability and proliferation assays in patient-derived lymphoblastoid cells

    PMID:40826479

    Open questions at the time
    • Single lab
    • Direct link between reduced WDR26 levels and specific CTLH substrate dysregulation in patient cells not shown

Open questions

Synthesis pass · forward-looking unresolved questions
  • How WDR26's signaling-scaffold role (Gβγ/PLCβ2/PI3K-AKT) and its CTLH E3 substrate-receptor role are integrated within a single cell, and what governs the choice between WDR26- and muskelin-defined CTLH proteomes, remain open.
  • No study reconciles the GPCR-scaffold and E3-ligase functions mechanistically
  • Upstream signals selecting WDR26 substrate panels are undefined
  • Full WDR26-specific substrate repertoire incompletely mapped

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060090 molecular adaptor activity 3 GO:0140096 catalytic activity, acting on a protein 3 GO:0098772 molecular function regulator activity 2 GO:0005198 structural molecule activity 1
Localization
GO:0005739 mitochondrion 2 GO:0005886 plasma membrane 2 GO:0005634 nucleus 1
Pathway
R-HSA-392499 Metabolism of proteins 4 R-HSA-162582 Signal Transduction 3 R-HSA-1643685 Disease 3
Complex memberships
CTLH/GID E3 ubiquitin ligase complex

Evidence

Reading pass · 15 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2004 WDR26 is a novel WD40 repeat, Gβ-like protein that, when overexpressed, suppresses MAPK signaling by inhibiting ELK-1 and c-fos SRE transcriptional activities mediated by MEKK1, acting as a negative regulator of the MAPK pathway. Overexpression in cells with transcriptional reporter assays (ELK-1 and SRE-driven luciferase) downstream of MEKK1 Journal of cellular biochemistry Medium 15378603
2011 WDR26 directly binds free Gβγ in vitro and forms a complex with endogenous Gβγ in SDF1α-stimulated Jurkat T cells; WDR26 is required for Gβγ-dependent PLCβ and PI3K activation and for leukocyte chemotaxis. WDR26 also controls RACK1 (a negative regulator) binding to Gβγ. In vitro direct binding assay, co-immunoprecipitation with endogenous Gβγ, siRNA knockdown with functional readouts (PLCβ/PI3K activation, chemotaxis, in vivo homing in SCID mice), WDR26 deletion mutant expression The Journal of biological chemistry High 22065575
2013 WDR26 functions as a scaffolding protein that directly binds both Gβγ and PLCβ2 (with overlapping but non-identical binding sites on Gβ1γ2), forms higher-order oligomers through its LisH-CTLH and WD40 domains, and promotes PLCβ2 membrane translocation and interaction with Gβγ, thereby enhancing PLCβ2 activation in leukocytes. Direct binding assays, co-immunoprecipitation, domain-mapping with deletion mutants, fluorescence imaging of PLCβ2 translocation, functional PLCβ2 activity assays The Journal of biological chemistry High 23625927
2016 WDR26 serves as a scaffold downstream of GPCR stimulation to assemble a specific signaling complex consisting of Gβγ, PI3Kβ, and AKT2, selectively promoting GPCR- (but not EGF receptor-) stimulated PI3K/AKT signaling in breast cancer cells. Disrupting this complex via WDR26 mutants abrogated PI3K/AKT activation and tumor growth/metastasis in an orthotopic xenograft model. siRNA knockdown, overexpression of WDR26 mutants disrupting complex assembly, signaling assays (pAKT, pPI3K), orthotopic xenograft mouse model Oncotarget High 26895380
2016 WDR26 binds Axin1 and acts as a negative regulator of canonical Wnt signaling by promoting ubiquitination and degradation of β-catenin; WDR26/Axin interaction is required for this effect. Co-immunoprecipitation (WDR26–Axin1 interaction), β-catenin ubiquitination assay, Wnt reporter assay, WDR26 overexpression/knockdown FEBS letters Medium 27098453
2016 WDR26 promotes hypoxia-induced mitophagy in cardiomyocytes (H9c2 cells) by increasing mitochondrial membrane potential and facilitating Parkin translocation to mitochondria, leading to increased mitochondrial protein ubiquitination. WDR26 overexpression/knockdown in H9c2 cells under hypoxia, Parkin translocation imaging, mitochondrial membrane potential measurement, ubiquitination assay Acta biochimica et biophysica Sinica Medium 27797717
2020 Wdr26, as part of the GID/CTLH E3 ubiquitin ligase complex, regulates ubiquitination and proteasomal degradation of nuclear proteins including lamin B during terminal erythropoiesis; loss of Wdr26 impairs lamin B degradation, blocks nuclear opening formation, and causes defective nuclear condensation and enucleation. Wdr26 knockout in mouse erythroblasts (enucleation defects), zebrafish knockdown (anemia), ubiquitination assays for lamin B, lamin B protein level measurement, CTLH/GID complex co-immunoprecipitation Blood High 31945154
2009 WDR26 overexpression suppresses H2O2-induced cell death in SH-SY5Y neuroblastoma cells and downregulates AP-1 transcriptional activity during oxidative stress; conversely, antisense ODN knockdown of WDR26 enhances H2O2-induced cell death. Overexpression and antisense ODN knockdown, cell viability assay, AP-1 luciferase reporter assay Neuroscience letters Low 19446606
2012 WDR26 localizes to mitochondria and inhibits cytochrome c release from mitochondria, thereby suppressing apoptosis in H9c2 cardiomyocytes under oxidative stress. Subcellular fractionation/localization assay, cytochrome c release assay, WDR26 overexpression with H2O2 treatment, apoptosis readout Free radical research Low 22448652
2024 WDR26 acts as a non-canonical substrate receptor within the CTLH E3 complex to bind NMNAT1 via an internal basic degron motif and mediate its ubiquitylation and cellular degradation independently of canonical GID/CTLH substrate receptors. YPEL5 inhibits this process by N-terminal degron mimicry of NMNAT1. Cryo-EM structures of NMNAT1- and YPEL5-bound WDR26-CTLH E3 complexes were determined. Cryo-EM structure determination, in vitro ubiquitylation assay, co-immunoprecipitation, degron mutagenesis, cellular degradation assays, YPEL5 knockout/overexpression Molecular cell High 38759627
2024 SKDEAS-associated WDR26 mutations impair CTLH E3 complex assembly and function; WDR26 homodimers bridge two core-CTLH E3 complexes to form supramolecular oval-shaped assemblies, mediates CTLH E3 binding to YPEL5, and functions as substrate receptor for transcriptional repressor HBP1. 15 of 16 patient-derived mutants impaired at least one of these functions. Structural modeling of WDR26, complementation assays in WDR26-KO cells engineered to lack CTLH supramolecular assemblies, functional assays for complex assembly, YPEL5 binding, and HBP1 substrate receptor activity FEBS letters High 38575527
2024 WDR26 and muskelin β-propeller proteins compete for binding to the CTLH complex scaffold in an interchangeable manner, forming separate WDR26- or muskelin-containing complexes with distinct proteomes. CTLH E3 ligase activity in HeLa cells is dictated by the interplay between WDR26 and muskelin; muskelin protein turnover is a major ubiquitin-dependent degradation event dependent on the CTLH complex. Proteomic experiments (mass spectrometry), WDR26 and muskelin knockout cell lines, co-immunoprecipitation, ubiquitin assays, mTOR inhibition experiments Communications biology High 39702571
2025 The CTLH-WDR26 E3 complex mediates ubiquitin-dependent degradation of UCK2 (rate-limiting enzyme of pyrimidine salvage pathway) during mTORC1 inhibition; UCK1, an isoform of UCK2, affects UCK2 turnover by influencing its subcellular localization. mTORC1 inhibition (rapamycin) with WDR26/CTLH knockdown/knockout, UCK2 half-life/degradation assays, ubiquitination assays, cellular localization experiments Cell reports High 39808525
2026 Wdr26 haploinsufficiency in mice stabilizes RUNX1T1 (a transcriptional coactivator) by impairing its ubiquitination and proteasomal degradation via the CTLH complex, leading to elevated MAP2 and disrupted dendritic/synaptic architecture. AAV-shRNA knockdown of Runx1t1 in neonatal Wdr26+/- mice reversed MAP2 overexpression and behavioral deficits. Wdr26 heterozygous KO mouse model, RUNX1T1 ubiquitination assay, MAP2 protein level measurement, AAV-shRNA rescue experiment, behavioral tests The Journal of clinical investigation High 42138082
2025 Missense variants in WDR26 associated with Skraban-Deardorff syndrome markedly reduce WDR26 protein levels through accelerated proteasomal degradation (reversed by proteasome inhibitor), while a frameshift variant reduces WDR26 mRNA via nonsense-mediated decay; both mechanisms result in loss of function and impaired cell proliferation. Cycloheximide chase, proteasome inhibitor treatment, mRNA stability assays, lymphoblastoid cell proliferation assay with patient-derived variants European journal of medical research Medium 40826479

Source papers

Stage 0 corpus · 22 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2016 Upregulated WDR26 serves as a scaffold to coordinate PI3K/ AKT pathway-driven breast cancer cell growth, migration, and invasion. Oncotarget 58 26895380
2020 Wdr26 regulates nuclear condensation in developing erythroblasts. Blood 55 31945154
2004 WDR26: a novel Gbeta-like protein, suppresses MAPK signaling pathway. Journal of cellular biochemistry 52 15378603
2017 WDR26 Haploinsufficiency Causes a Recognizable Syndrome of Intellectual Disability, Seizures, Abnormal Gait, and Distinctive Facial Features. American journal of human genetics 51 28686853
2016 WDR26 is a new partner of Axin1 in the canonical Wnt signaling pathway. FEBS letters 35 27098453
2016 WDR26 promotes mitophagy of cardiomyocytes induced by hypoxia through Parkin translocation. Acta biochimica et biophysica Sinica 31 27797717
2011 The WD40 repeat protein WDR26 binds Gβγ and promotes Gβγ-dependent signal transduction and leukocyte migration. The Journal of biological chemistry 31 22065575
2024 Non-canonical substrate recognition by the human WDR26-CTLH E3 ligase regulates prodrug metabolism. Molecular cell 29 38759627
2009 A novel WD-40 repeat protein WDR26 suppresses H2O2-induced cell death in neural cells. Neuroscience letters 29 19446606
2013 WDR26 functions as a scaffolding protein to promote Gβγ-mediated phospholipase C β2 (PLCβ2) activation in leukocytes. The Journal of biological chemistry 22 23625927
2012 A novel WD-repeat protein, WDR26, inhibits apoptosis of cardiomyocytes induced by oxidative stress. Free radical research 19 22448652
2025 mTORC1 regulates the pyrimidine salvage pathway by controlling UCK2 turnover via the CTLH-WDR26 E3 ligase. Cell reports 13 39808525
2024 Skraban-Deardorff intellectual disability syndrome-associated mutations in WDR26 impair CTLH E3 complex assembly. FEBS letters 13 38575527
2021 Expanding the clinical phenotype of the ultra-rare Skraban-Deardorff syndrome: Two novel individuals with WDR26 loss-of-function variants and a literature review. American journal of medical genetics. Part A 13 33675273
2021 Skraban-Deardorff syndrome: Six new cases of WDR26-related disease and expansion of the clinical phenotype. Clinical genetics 11 33506510
2024 Interplay between β-propeller subunits WDR26 and muskelin regulates the CTLH E3 ligase supramolecular complex. Communications biology 10 39702571
2021 WDR26 and MTF2 are therapeutic targets in multiple myeloma. Journal of hematology & oncology 9 34876184
2022 Two Novel Variants of WDR26 in Chinese Patients with Intellectual Disability. Genes 7 35627197
2024 Novel loss-of-function variants in WDR26 cause Skraban-Deardorff syndrome in two Chinese patients. Frontiers in pediatrics 2 39363971
2026 miR-34 regulates stress-induced depression-like state through the WDR26 ortholog melancholy in Drosophila. Research square 0 41994129
2026 Wdr26 insufficiency causes Skraban-Deardorff syndrome-like neurodevelopmental deficits in mice. The Journal of clinical investigation 0 42138082
2025 WDR26-related Skraban-Deardorff syndrome: clinical, genetic and pathomechanistic insights. European journal of medical research 0 40826479

Missed literature

Know a paper Affinage missed for WDR26? Flag it for the maintainers and the community.

No submissions yet.